|Bid||285.02 x 800|
|Ask||296.26 x 1100|
|Day's Range||288.31 - 297.64|
|52 Week Range||271.57 - 442.00|
|Beta (3Y Monthly)||0.86|
|PE Ratio (TTM)||16.43|
|Earnings Date||Nov 4, 2019 - Nov 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||386.33|
The company's treatment for nasal polyps receives positive feedback from the European Medicines Agency's Committee for Medicinal Products for Human Use.
TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Sept. 20, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that The Lancet has published detailed positive results from two Phase 3 trials evaluating the safety and efficacy of Dupixent® (dupilumab) in adults with recurring severe chronic rhinosinusitis with nasal polyps (CRSwNP) despite previous treatment with surgery and/or systemic corticosteroids. Results published in The Lancet demonstrated that adding Dupixent to the standard-of-care corticosteroid nasal spray reduced nasal polyp size and nasal congestion severity (co-primary endpoints). Dupixent also reduced chronic sinus disease associated with nasal polyps and improved sense of smell.
TARRYTOWN, N.Y. and PARIS, Sept. 20, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Dupixent® (dupilumab) in a third indication. The CHMP recommended Dupixent be approved as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe chronic rhinosinusitis with nasal polyposis (CRSwNP) for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi, in partnership with the National Eczema Association (NEA), today launched the next phase of Understand AD, a disease awareness initiative focused on educating about moderate-to-severe atopic dermatitis (AD). Teenagers face many challenges, and growing up with AD can impact the ups and downs and transitions to young adulthood even harder. The new phase of Understand AD deploys a team of experts – a dermatologist, psychotherapist and peer living with severe AD, together known as The Understand AD Squad – into the home of Isaiah Dixon, a 17-year-old who has been living with severe AD since he was two years old.
Alnylam (ALNY) starts phase III APOLLO-B study on its lead drug Onpattro for treating transthyretin amyloidosis with cardiomyopathy. Shares rise.
Regeneron is one of only four companies in the biotechnology sector to be included on the DJSI World list. DJSI World is a leading global index comprised of corporate leaders in environmental, social and governance (ESG) practices, which recognizes the top 10 percent most sustainable companies in each industry.
On the stump, if there's one thing that both Republican and Democratic politicians have long claimed to support, it's lower drug prices. And when rumors start buzzing that the government may be about to intervene, then biotech stocks often get slammed…some fairly, and some not (as we'll see).That's just what happened in the past week.House Speaker Nancy Pelosi has a tougher proposal on her agenda than, say, President Trump. While the Trump administration is more interested in importing lower-priced versions of the drugs from Canada, Pelosi wants to apply direct pressure to pharmaceutical companies.InvestorPlace - Stock Market News, Stock Advice & Trading TipsSpecifically, Pelosi wants to allow the Dept. of Health & Human Services to negotiate prices for Medicare Part D drug plans directly with drug manufacturers. (That would, effectively, eject pharmacy benefit managers and insurance companies from the negotiating table.)Several biotech stocks have taken big hits on the regulatory rumors. Some of the Big Pharma crowd even showed up on the list of three-year lows last week! Let's review - because while some deserve to be sold, one big mover is actually on my Top 5 Stocks list for Breakthrough Stocks. * 7 Discount Retail Stocks to Buy for a Recession First we have Biogen (NASDAQ:BIIB), a potential target of Pelosi's proposal. With its famously pricey drug for spinal muscular atrophy, Spiranza, Biogen may well come into Democrats' crosshairs here. BIIB stock dropped sharply last Friday and again on Thursday.You may think that with pricing like $750,000 for your first year of Spiranza, Biogen would be printing money. But Spiranza just picked up a competitor from Novartis (NYSE:NVS). And below is the full picture on BIIB stock from my Portfolio Grader:While Biogen passes some of my profitability tests, it gets an F for Earnings Momentum, and Sales Growth is lackluster as well. Most concerning is the fact that BIIB stock got a D for its Quantitative Grade - my proprietary measure of institutional buying pressure.Regeneron Pharmaceuticals (NASDAQ:REGN) is looking even worse. The stock got off to a rough start this week, and while it's clawed back somewhat, it's still down 8% in the past month. For its part, Regeneron has a cholesterol drug (Praluent) that was so expensive that it eventually succumbed to pressure, reduced prices by 60%, and yet it still costs $5,850 a year.Here's REGN's Report Card:As you see above, Regeneron just does not measure up on Operating Margin Growth, Earnings Growth, Earnings Momentum or its Quantitative Grade.Then there's Repligen (NASDAQ:RGEN). While it may have a similar name and ticker, RGEN has much stronger fundamentals. Shares took an even bigger hit - but this is a much more interesting case.Repligen is a unique biotech: This company actually has no drugs of its own, but rather, its products are used in drug manufacturing.Repligen hit the biotechnology scene back in 1981, as it started to develop Protein A ligands to aid in the production of biologic treatments. The company has expanded rapidly since then, and was even named one of the Top 100 fastest-growing companies in the U.S. in 2018. Today, along with Protein A ligands, Repligen offers several products and solutions to enhance the production of biologic drugs.Strong demand for Repligen's biologic solutions was apparent in the company's second-quarter earnings report. The company reported 48% annual revenue growth and 121.4% annual earnings growth. Plus, second-quarter earnings of $0.31 per share crushed estimates for $0.25 per share by 24%.Given the strong second-quarter results, analysts have increased full-year 2019 forecasts in the past two months. Analysts are forecasting 32.9% annual earnings growth and 37.1% annual sales growth.This all makes for a very impressive Report Card on RGEN, as you see here:So, when this kind of stock drops as hard as RGEN just did, I view it as a chance to pick up shares at "bargain basement" prices for a great, long-term play. There's Something Else That Sets These Breakthrough Stocks ApartIf you take a look at RGEN stock, you'll notice its much smaller market cap of $4 billion, versus giant biotech stocks like BIIB and REGN with $30 billion (or more)!If you're a growth investor - and I certainly am; I've made my career this way - then you've got to look at elite small-caps like this. With growth statistics like RGEN's (and my other Breakthrough Stocks), the sky is the limit.RGEN is 4 on my list of Top 5 Stocks. To get my buy price - and the rest of the list - check out Breakthrough Stocks now. When you do, you'll learn all about my "Quantum A" system for identifying the best small-cap investments.Ultimately, spotting the right investment is simple. You buy when the company achieves a Quantum A …and you sell when it disappears.You don't fall in love. You certainly don't fall for hype. You may return to that stock someday - but with my system, you know exactly when it's time to take profits off the table.That's why I always say: There's no luck and very little skill behind my own success - just hard work. And the result: a proprietary system for picking the best investments of the day. It's made it easy to nab market-beating returns - for double your money (or better).I'm eager to show you what my system is picking up now. Click here to find out more.Louis Navellier had an unconventional start, as a grad student who accidentally built a market-beating stock system -- with returns rivaling even Warren Buffett. In his latest feat, Louis discovered the "Master Key" to profiting from the biggest tech revolution of this (or any) generation. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Big IPO Stocks From 2019 to Watch * 7 Discount Retail Stocks to Buy for a Recession * 7 Stocks to Buy Benefiting From Millennial Money The post 3 Biotech Stocks That Show The Good, The Bad and the Ugly Side of This Sector appeared first on InvestorPlace.
Adverum Biotechnologies (ADVM) announces data from one cohort of an early-stage study, evaluating its gene therapy candidate, ADVM-022, in patients with wet AMD.
The FDA is expected to give its decision on Allergan's (AGN) BLA for its anti-VEGF product, abicipar pegol in mid-2020, while the EMA's decision is expected in the second half of 2020.
Biogen Inc. (BIIB), Regeneron Pharmaceuticals Inc. (REGN), Canon Inc. (CAJ) and Annaly Capital Management Inc. (NLY) have declined to their respective three-year lows Continue reading...
Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
A combination regimen of Esperion (ESPR) and Merck's Zetia significantly improves bad cholesterol (LDL-C) levels in patients with both hypercholesterolemia and type II diabetes.
The concept of support is not one of the first things you need to understand as an investor, but you will find it a powerful tool once you learn to use it.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 28) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Down ...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi announced today that the U.S. District Court for the District of Delaware ruled in their favor and found as a matter of law that Amgen's asserted patent claims for antibodies targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) are invalid based on lack of enablement. "Today's decision by the U.S. District Court for the District of Delaware validates our position that Amgen's patents are overly broad and invalid," said Joseph LaRosa, Executive Vice President, General Counsel and Secretary, Regeneron.
The ruling from U.S. District Judge Richard Andrews in Wilmington, Delaware was the latest reversal of fortune in a long-running lawsuit in which Amgen is seeking to stop French drugmaker Sanofi and U.S. biotech Regeneron from selling their drug Praluent. Repatha and Praluent won U.S. approval about two weeks apart in July of 2016.
A U.S. judge on Wednesday set aside a jury verdict that found Amgen Inc patents on its cholesterol drug Repatha were valid, handing a victory to Regeneron Pharmaceuticals Inc and Sanofi SA, which sells a rival drug. The ruling from U.S. District Judge Richard Andrews in Wilmington, Delaware was the latest reversal of fortune in a long-running lawsuit in which Amgen is seeking to stop French drugmaker Sanofi and U.S. biotech Regeneron from selling their drug Praluent.
A newer technology that uses small-interfering RNA to the same effect might serve a major blow to the anti-cholesterol antibodies, including Amgen ’s Repatha.
The project is part of the $800 million manufacturing complex Regeneron is constructing on 130 acres off Tempel Lane in East Greenbush that is visible to the 46,400 cars and trucks that travel along Interstate 90 through Rensselaer County every day.